GLP-1s like Ozempic and Wegovy are no longer in short supply, yet they still can cost more than $1,000 a month out of pocket. Wall Street Journal contributor Cheryl Winokur Munk joins host Callum Borchers to dig into why some people pay much more for weight-loss drugs than others. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
#2426 - Cameron Hanes & Adam Greentree
16 Dec 2025
The Joe Rogan Experience
#487 – Irving Finkel: Deciphering Secrets of Ancient Civilizations & Flood Myths
12 Dec 2025
Lex Fridman Podcast
#2425 - Ethan Hawke
11 Dec 2025
The Joe Rogan Experience
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show